The disease-related pathological changes and serum indicators in the CUMR and CURD models are highly similar to those in patients in the clinic, and therapeutic medicines can effectively improve brain function and behavior in these models
Maybe just a fraction of each dose
What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use
[99], which involved transplantations of fecal microbiota obtained from depressed patients into a microbiota-depleted antibiotic rat model, the animals developed depressive-like symptoms, which were manifested by behavioral differences such as decreased sucrose intake in the sucrose preference test, a lower number of entries to an open arm in the elevated plus-maze test, and an increase in a plasma kynurenine/tryptophan ratio
Non-template controls were included to check for any significant levels of contaminants
